The online version of this article (doi:10.1186/1475-2867-12-27) contains supplementary material, which is available to authorized users.
There are no competing interests.
NMA designed and did the experiments and wrote the manuscript; JDM helped with sample processing and microscopy, TK helped with proliferation and apoptosis experiments, JCB provided VSVΔ51 virus, and FFL conceived the study and obtained funding.All authors read and approved the final manuscript.
Head and neck squamous cell carcinoma (HNSCC) is the 5th most common cancer worldwide. Locally advanced HNSCC are treated with either radiation or chemo-radiotherapy, but still associated with high mortality rate, underscoring the need to develop novel therapies. Oncolytic viruses have been garnering increasing interest as anti-cancer agents due to their preferential killing of transformed cells. In this study, we evaluated the therapeutic potential of mutant vesicular stomatitis virus (VSVΔ51) against the human hypopharyngeal FaDu tumour model in vitro and in vivo.
Our data demonstrated high toxicity of the virus against FaDu cells in vitro, which was associated with induction of apoptosis. In vivo, systemic injection of 1 × 109 pfu had minimal effect on tumour growth; however, when combined with two doses of ionizing radiation (IR; 5 Gy each) or a single injection of the vascular disrupting agent (ZD6126), the virus exhibited profound suppression of tumour growth, which translated to a prolonged survival in the treated mice. Concordantly, VSVΔ51 combined with ZD6126 led to a significant increase in viral replication in these tumours.
Our data suggest that the combinations of VSVΔ51 with either IR or ZD6126 are potentially novel therapeutic opportunities for HNSCC.
Giralt J, Benavente S, Arguis M: Optimizing approaches to head and neck cancer: strengths and weaknesses in multidisciplinary treatments of locally advanced disease. Ann Oncol. 2008, 19 (Suppl 7): vii195-199. PubMed
Melcher A, Parato K, Rooney CM, Bell JC: Thunder and lightning: immunotherapy and oncolytic viruses collide. Mol Ther. 19 (6): 1008-1016.
Stojdl DF, Lichty BD, tenOever BR, Paterson JM, Power AT, Knowles S, Marius R, Reynard J, Poliquin L, Atkins H: VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents. Cancer Cell. 2003, 4 (4): 263-275. 10.1016/S1535-6108(03)00241-1. CrossRefPubMed
Alain T, Lun X, Martineau Y, Sean P, Pulendran B, Petroulakis E, Zemp FJ, Lemay CG, Roy D, Bell JC: Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad. 2010, 107 (4): 1576-1581. 10.1073/pnas.0912344107. CrossRef
Alajez NM, Mocanu JD, Shi W, Chia MC, Breitbach CJ, Hui AB, Knowles S, Bell JC, Busson P, Takada K: Efficacy of systemically administered mutant vesicular stomatitis virus (VSVDelta51) combined with radiation for nasopharyngeal carcinoma. Clin Cancer Res. 2008, 14 (15): 4891-4897. 10.1158/1078-0432.CCR-07-4134. CrossRefPubMed
Schepelmann S, Ogilvie LM, Hedley D, Friedlos F, Martin J, Scanlon I, Chen P, Marais R, Springer CJ: Suicide gene therapy of human colon carcinoma xenografts using an armed oncolytic adenovirus expressing carboxypeptidase G2. Cancer Res. 2007, 67 (10): 4949-4955. 10.1158/0008-5472.CAN-07-0297. CrossRefPubMed
Yong RL, Shinojima N, Fueyo J, Gumin J, Vecil GG, Marini FC, Bogler O, Andreeff M, Lang FF: Human bone marrow-derived mesenchymal stem cells for intravascular delivery of oncolytic adenovirus Delta24-RGD to human gliomas. Cancer Res. 2009, 69 (23): 8932-8940. 10.1158/0008-5472.CAN-08-3873. PubMedCentralCrossRefPubMed
Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ, Nieva J, Hwang TH, Moon A, Patt R: Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature. 7362: 99-102.
Advani SJ, Markert JM, Sood RF, Samuel S, Gillespie GY, Shao MY, Roizman B, Weichselbaum RR: Increased oncolytic efficacy for high-grade gliomas by optimal integration of ionizing radiation into the replicative cycle of HSV-1. Gene Ther. 11: 1098-1102.
Mocanu JD, Yip KW, Alajez NM, Shi W, Li JH, Lunt SJ, Moriyama EH, Wilson BC, Milosevic M, Lo KW: Imaging the modulation of adenoviral kinetics and biodistribution for cancer gene therapy. Mol Ther. 2007, 15 (5): 921-929. PubMed
- Enhanced vesicular stomatitis virus (VSVΔ51) targeting of head and neck cancer in combination with radiation therapy or ZD6126 vascular disrupting agent
Nehad M Alajez
Joseph D Mocanu
John C Bell
- BioMed Central
Neu im Fachgebiet Onkologie
e.Med Kampagnen-Visual, Mail Icon II